Page last updated: 2024-08-07 15:52:50
Cytochrome P450 2C8
A cytochrome P450 2C8 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P10632]
Synonyms
EC 1.14.14.1;
CYPIIC8;
Cytochrome P450 IIC2;
Cytochrome P450 MP-12;
Cytochrome P450 MP-20;
Cytochrome P450 form 1;
S-mephenytoin 4-hydroxylase
Research
Bioassay Publications (61)
| Timeframe | Studies on this Protein(%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (16.39) | 29.6817 |
| 2010's | 42 (68.85) | 24.3611 |
| 2020's | 9 (14.75) | 2.80 |
Compounds (74)
Drugs with Inhibition Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| acetazolamide | Homo sapiens (human) | Ki | 0.0354 | 4 | 8 |
| amiodarone | Homo sapiens (human) | Ki | 1.5000 | 1 | 1 |
| verapamil | Homo sapiens (human) | Ki | 17.5000 | 1 | 1 |
| fluoxetine | Homo sapiens (human) | Ki | 294.0000 | 1 | 1 |
| gemfibrozil | Homo sapiens (human) | IC50 | 4.1000 | 1 | 1 |
| phenelzine | Homo sapiens (human) | Ki | 1.2000 | 1 | 1 |
| isoniazid | Homo sapiens (human) | Ki | 374.0000 | 1 | 1 |
| ketoconazole | Homo sapiens (human) | IC50 | 0.0600 | 1 | 1 |
| metyrapone | Homo sapiens (human) | IC50 | 5.0000 | 1 | 1 |
| nortriptyline | Homo sapiens (human) | Ki | 49.9000 | 1 | 1 |
| propranolol | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| vorinostat | Homo sapiens (human) | IC50 | 0.0903 | 2 | 3 |
| sulfaphenazole | Homo sapiens (human) | IC50 | 130.0000 | 1 | 1 |
| ticlopidine | Homo sapiens (human) | Ki | 30.3667 | 3 | 3 |
| 2,2-dimethylbutyric acid | Homo sapiens (human) | IC50 | 10,000.0000 | 1 | 1 |
| tranylcypromine | Homo sapiens (human) | IC50 | 6.2000 | 1 | 1 |
| mifepristone | Homo sapiens (human) | IC50 | 1.5000 | 2 | 2 |
| nitrogenase stabilizing-protective protein, bacteria | Homo sapiens (human) | GI50 | 1.8000 | 1 | 1 |
| clopidogrel | Homo sapiens (human) | Ki | 14.3000 | 1 | 1 |
| proadifen hydrochloride | Homo sapiens (human) | IC50 | 19.0000 | 1 | 1 |
| pirlindole | Homo sapiens (human) | IC50 | 36.0000 | 1 | 1 |
| gemfibrozil 1-o-acylglucuronide | Homo sapiens (human) | IC50 | 28.0000 | 1 | 1 |
| 6-paradol | Homo sapiens (human) | IC50 | 4.8000 | 2 | 2 |
| cp-55,940 | Homo sapiens (human) | IC50 | 0.0008 | 1 | 1 |
| desethylamodiaquine | Homo sapiens (human) | IC50 | 20.0000 | 2 | 2 |
| gefitinib | Homo sapiens (human) | IC50 | 0.1510 | 1 | 1 |
| adenosine amine congener | Homo sapiens (human) | Ki | 0.0104 | 1 | 1 |
| tariquidar | Homo sapiens (human) | IC50 | 45.3000 | 1 | 1 |
| anidulafungin | Homo sapiens (human) | IC50 | 14.7500 | 2 | 2 |
| n-hydroxy-2,2-diphenylacetamide | Homo sapiens (human) | IC50 | 0.6500 | 1 | 1 |
| adenosine-5'-(n-ethylcarboxamide) | Homo sapiens (human) | Ki | 0.0068 | 1 | 1 |
| l 731988 | Homo sapiens (human) | IC50 | 0.1700 | 1 | 1 |
| bay 57-1293 | Homo sapiens (human) | Ki | 0.2565 | 3 | 7 |
| n(6)-cyclopentyladenosine | Homo sapiens (human) | Ki | 0.0018 | 1 | 1 |
| quercetin | Homo sapiens (human) | IC50 | 13.5000 | 2 | 2 |
| montelukast | Homo sapiens (human) | IC50 | 0.7000 | 2 | 2 |
| topiramate | Homo sapiens (human) | Ki | 0.0100 | 1 | 1 |
| (3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone | Homo sapiens (human) | IC50 | 0.1400 | 1 | 1 |
| opc-67683 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| orteronel | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| CB-13 | Homo sapiens (human) | IC50 | 0.0150 | 1 | 1 |
| tofacitinib | Homo sapiens (human) | IC50 | 0.0014 | 1 | 1 |
| way 181187 | Homo sapiens (human) | IC50 | 500.0000 | 1 | 1 |
| bibw 2992 | Homo sapiens (human) | IC50 | 0.0370 | 1 | 1 |
| gsk 369796 | Homo sapiens (human) | IC50 | 23.0000 | 1 | 1 |
| msdc-0160 | Homo sapiens (human) | IC50 | 26.0000 | 1 | 1 |
| bms-626529 | Homo sapiens (human) | IC50 | 25.0000 | 1 | 1 |
| amodiaquine hydrochloride | Homo sapiens (human) | IC50 | 2.7000 | 2 | 2 |
| buparlisib | Homo sapiens (human) | IC50 | 0.0400 | 1 | 1 |
| lumacaftor | Homo sapiens (human) | IC50 | 12.0000 | 1 | 1 |
| bms 687453 | Homo sapiens (human) | IC50 | 40.0000 | 1 | 1 |
| serlopitant | Homo sapiens (human) | IC50 | 58.0000 | 1 | 1 |
| montelukast sodium | Homo sapiens (human) | Ki | 11.0000 | 1 | 1 |
| pci 32765 | Homo sapiens (human) | IC50 | 3.9595 | 2 | 2 |
| glasdegib | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| e-52862 | Homo sapiens (human) | IC50 | 10.0000 | 2 | 2 |
| (3R)-4-[2-(1H-indol-4-yl)-6-(1-methylsulfonylcyclopropyl)-4-pyrimidinyl]-3-methylmorpholine | Homo sapiens (human) | IC50 | 0.0030 | 1 | 1 |
| glpg0634 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| kaf156 | Homo sapiens (human) | IC50 | 6.0000 | 1 | 1 |
| pf 00868554 | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| dolutegravir | Homo sapiens (human) | IC50 | 90.0000 | 1 | 1 |
| MK-8353 | Homo sapiens (human) | IC50 | 4.2500 | 2 | 2 |
| onc201 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| azd3759 | Homo sapiens (human) | IC50 | 0.0500 | 1 | 1 |
| 3-chloro-5-(6-(5-fluoropyridin-2-yl)pyrimidin-4-yl)benzonitrile | Homo sapiens (human) | IC50 | 15.8489 | 1 | 1 |
| 2-[(4-chlorophenyl)methylthio]-1,5,6,7-tetrahydrocyclopenta[d]pyrimidin-4-one | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
| mk 6892 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| 4-[[(4-oxo-1,5,6,7-tetrahydrocyclopenta[d]pyrimidin-2-yl)thio]methyl]benzoic acid methyl ester | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
Drugs with Activation Measurements
Drugs with Other Measurements
Design, Synthesis, and X-ray of Selenides as New Class of Agents for Prevention of Diabetic Cerebrovascular Pathology.ACS medicinal chemistry letters, , May-10, Volume: 9, Issue:5, 2018
Lead Development of Thiazolylsulfonamides with Carbonic Anhydrase Inhibitory Action.Journal of medicinal chemistry, , 04-13, Volume: 60, Issue:7, 2017
Design, synthesis and evaluation of antiproliferative activity of melanoma-targeted histone deacetylase inhibitors.Bioorganic & medicinal chemistry letters, , 02-15, Volume: 27, Issue:4, 2017
Design, synthesis and preliminary bioactivity studies of 1,2-dihydrobenzo[d]isothiazol-3-one-1,1-dioxide hydroxamic acid derivatives as novel histone deacetylase inhibitors.Bioorganic & medicinal chemistry, , Mar-01, Volume: 22, Issue:5, 2014
Discovery of a Potent Steroidal Glucocorticoid Receptor Antagonist with Enhanced Selectivity against the Progesterone and Androgen Receptors (OP-3633).Journal of medicinal chemistry, , 07-25, Volume: 62, Issue:14, 2019
Discovery of a Potent and Selective Steroidal Glucocorticoid Receptor Antagonist (ORIC-101).Journal of medicinal chemistry, , 09-13, Volume: 61, Issue:17, 2018
Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.Journal of medicinal chemistry, , Apr-09, Volume: 52, Issue:7, 2009
Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.Journal of medicinal chemistry, , Mar-12, Volume: 52, Issue:5, 2009
Evaluation of Amides, Carbamates, Sulfonamides, and Ureas of 4-Prop-2-ynylidenecycloalkylamine as Potent, Selective, and Bioavailable Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5.Journal of medicinal chemistry, , 02-14, Volume: 62, Issue:3, 2019
Development of Robust 17(Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019
[no title available]Journal of medicinal chemistry, , 06-09, Volume: 65, Issue:11, 2022
Synthesis, Characterization, and Preclinical Evaluation of a Small-Molecule Prostate-Specific Membrane Antigen-Targeted Monomethyl Auristatin E Conjugate.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.Journal of medicinal chemistry, , Apr-09, Volume: 52, Issue:7, 2009
Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.Journal of medicinal chemistry, , Mar-12, Volume: 52, Issue:5, 2009
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.Journal of medicinal chemistry, , 09-12, Volume: 62, Issue:17, 2019
Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.Bioorganic & medicinal chemistry letters, , 09-15, Volume: 28, Issue:17, 2018
Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.Bioorganic & medicinal chemistry letters, , 11-15, Volume: 28, Issue:21, 2018
Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor.Journal of medicinal chemistry, , Mar-12, Volume: 52, Issue:5, 2009
Enables
This protein enables 10 target(s):
| Target | Category | Definition |
|---|
| monooxygenase activity | molecular function | Catalysis of the incorporation of one atom from molecular oxygen into a compound and the reduction of the other atom of oxygen to water. [ISBN:0198506732] |
| iron ion binding | molecular function | Binding to an iron (Fe) ion. [GOC:ai] |
| protein binding | molecular function | Binding to a protein. [GOC:go_curators] |
| arachidonic acid epoxygenase activity | molecular function | Catalysis of an NADPH- and oxygen-dependent reaction that converts arachidonic acid to a cis-epoxyeicosatrienoic acid. [http://lipidlibrary.aocs.org/Lipids/eic_hete/index.htm, PMID:10681399, PMID:18952572] |
| retinoic acid 4-hydroxylase activity | molecular function | Catalysis of the conversion of retinoic acid to 4-hydroxy-retinoic acid. [PMID:19519282, PMID:9250660] |
| caffeine oxidase activity | molecular function | Catalysis of the reaction: caffeine + O2 + 2 H+ + 2 e- = 1,3,7-trimethyluric acid + H2O. [RHEA:47148] |
| aromatase activity | molecular function | Catalysis of the reduction of an aliphatic ring to yield an aromatic ring. [GOC:cb] |
| estrogen 16-alpha-hydroxylase activity | molecular function | Catalysis of the reaction: estrogen + donor-H2 + O2 = 16-alpha-hydroxyestrogen + H2O. [GOC:BHF] |
| heme binding | molecular function | Binding to a heme, a compound composed of iron complexed in a porphyrin (tetrapyrrole) ring. [GOC:ai] |
| oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | molecular function | Catalysis of an oxidation-reduction (redox) reaction in which hydrogen or electrons are transferred from reduced flavin or flavoprotein and one other donor, and one atom of oxygen is incorporated into one donor. [GOC:mah] |
Located In
This protein is located in 3 target(s):
| Target | Category | Definition |
|---|
| endoplasmic reticulum membrane | cellular component | The lipid bilayer surrounding the endoplasmic reticulum. [GOC:mah] |
| plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
| intracellular membrane-bounded organelle | cellular component | Organized structure of distinctive morphology and function, bounded by a single or double lipid bilayer membrane and occurring within the cell. Includes the nucleus, mitochondria, plastids, vacuoles, and vesicles. Excludes the plasma membrane. [GOC:go_curators] |
Active In
This protein is active in 2 target(s):
| Target | Category | Definition |
|---|
| cytoplasm | cellular component | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. [ISBN:0198547684] |
| intracellular membrane-bounded organelle | cellular component | Organized structure of distinctive morphology and function, bounded by a single or double lipid bilayer membrane and occurring within the cell. Includes the nucleus, mitochondria, plastids, vacuoles, and vesicles. Excludes the plasma membrane. [GOC:go_curators] |
Involved In
This protein is involved in 13 target(s):
| Target | Category | Definition |
|---|
| lipid hydroxylation | biological process | The covalent attachment of a hydroxyl group to one or more fatty acids in a lipid. [GOC:hjd, PMID:15658937] |
| organic acid metabolic process | biological process | The chemical reactions and pathways involving organic acids, any acidic compound containing carbon in covalent linkage. [ISBN:0198506732] |
| xenobiotic metabolic process | biological process | The chemical reactions and pathways involving a xenobiotic compound, a compound foreign to the organim exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical. [GOC:cab2, GOC:krc] |
| steroid metabolic process | biological process | The chemical reactions and pathways involving steroids, compounds with a 1,2,cyclopentanoperhydrophenanthrene nucleus. [ISBN:0198547684] |
| estrogen metabolic process | biological process | The chemical reactions and pathways involving estrogens, C18 steroid hormones that can stimulate the development of female sexual characteristics. Also found in plants. [ISBN:0198506732] |
| epoxygenase P450 pathway | biological process | The chemical reactions and pathways by which arachidonic acid is converted to other compounds including epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids. [GOC:mah, PMID:17979511] |
| xenobiotic catabolic process | biological process | The chemical reactions and pathways resulting in the breakdown of a xenobiotic compound, a compound foreign to the organim exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical. [GOC:jl, GOC:krc] |
| retinol metabolic process | biological process | The chemical reactions and pathways involving retinol, one of the three compounds that makes up vitamin A. [GOC:jl, http://www.indstate.edu/thcme/mwking/vitamins.html, PMID:1924551] |
| retinoic acid metabolic process | biological process | The chemical reactions and pathways involving retinoic acid, one of the three components that makes up vitamin A. [GOC:jl, http://www.indstate.edu/thcme/mwking/vitamins.html] |
| long-chain fatty acid biosynthetic process | biological process | The chemical reactions and pathways resulting in the formation of a long-chain fatty acid. A long-chain fatty acid has an aliphatic tail containing 13 to 22 carbons. [PMID:18390550] |
| icosanoid biosynthetic process | biological process | The chemical reactions and pathways resulting in the formation of icosanoids, any of a group of C20 polyunsaturated fatty acids. [ISBN:0198506732] |
| oxidative demethylation | biological process | The process of removing one or more methyl groups from a molecule, involving the oxidation (i.e. electron loss) of one or more atoms in the substrate. [GOC:BHF, GOC:mah, GOC:rl] |
| omega-hydroxylase P450 pathway | biological process | The chemical reactions and pathways by which arachidonic acid is converted to other compounds initially by omega-hydroxylation. [GOC:mw, PMID:10681399] |